GERN Geron Corporation
USHealthcareAs of 2026-07-08 16:00
Why GERN matters now
Geron Corporation (GERN) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.56 with +4.70% on the session and $1.00B in market capitalization; recent performance reads 1-month +3.28% and YTD -4.55%.
The latest financial table shown here is Q1 2026, with revenue of $51.8M, net income of $-3.6M, and EPS of $-0.01. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -15.6%.
The latest indexable market news headline is "Geron Corporation: Commercial Performance Could Dovetail With IMpactMF Run-Up" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $6.00; recent insider activity includes Bir Dawn Carter filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.68
P/S
4.12
EV/EBITDA
-26.78
DCF Value
$-7.33
FCF Yield
-15.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
86.6%
Operating Margin
-19.1%
Net Margin
-35.5%
ROE
-28.9%
ROA
-13.0%
ROIC
-7.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $51.8M | $-3.6M | $-0.01 |
| Q4 2025 | $48.0M | $-31.1M | $-0.05 |
| FY 2025 | $183.9M | $-85.8M | $-0.13 |
| Q3 2025 | $47.2M | $-18.4M | $-0.03 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$5.89
Target (Median)
$6.00
Target Range
$4.00 - $8.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.60
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.